A treatment, known as KEDRAB (Rabies Immune Globulin [Human]), currently used in the prevention of rabies has been demonstrated to be safe and effective for patients age 17 and under. Results published...

Rabies post exposure prophylaxis, or PEP, consists of a rabies vaccine series and human rabies immune globulin (HRIG). Kedrion Biopharma’s human rabies immune globulin, Kedrab, was FDA approved in 2017....

Fort Lee, New Jersey based company, Kedrion Biopharma and Israeli company, Kamada Ltd. announced that KEDRAB™ [rabies immune globulin (Human)] has received U.S. Food and Drug Administration (FDA)...